New ALS drug headed for phase II trial

The purpose of the phase IIa trial is to determine the safety and tolerability of TDI-132 in ALS patients.

http://www.sciencedaily.com/releases/2013/10/131025135257.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine%2Fpharmacology+%28ScienceDaily%3A+Health+%26+Medicine+News+--+Pharmacology%29